Arecor Therapeutics PLC (AIM:AREC) said it is teaming with US med-tech giant Medtronic to develop a new, high-concentration, thermostable insulin designed specifically for use in the latter's next-generation implantable insulin pumps.
Arecor believes there is the potential for 'significant advancements' in treatment for a group of diabetes patients who find limited benefits from conventional therapies.
And, by reducing the need for frequent pump maintenance, there is also the scope to simplify care and cut costs.
"Our leadership in this field has been demonstrated through our best-in-class ultra-rapid acting clinical development programmes (AT278 & AT247)," said Arecor CEO Sarah Howell.
"Within the diabetes field more broadly we are seeing the rise of innovative delivery devices, including longer-wear and miniaturised pumps that are continually improving treatment options for patients.
"We are excited to play our part in this progress with the development of a highly differentiated insulin with the potential to transform treatment for an extremely vulnerable patient group. This collaboration is one of many we hope to enable, to further enhance the benefits of these next-generation devices."